Jean-Louis Dasseux, Ph.D., M.B.A.
President and CEO, Cerenis Therapeutics
A co-founder of Cerenis and is one of the world’s leading experts in lipid metabolism and lipid-protein interaction. He was the inventor of a high-capacity reverse lipid transport peptide (ETC-642) and a series of small molecule compounds that raise HDL levels. Dr. Dasseux was formerly Vice President of Chemistry and Technology at Esperion Therapeutics. Before joining Esperion, he was Director of Research for the French pharmaceutical company Fournier, where he established and managed its research center in Heidelberg, Germany.
Narendra Lalwani, Ph.D, M.B.A.
Chief Scientific Officer
Dr. Lalwani has over 20 years of experience in pharmaceutical R&D on cardiovascular and metabolic disorders at Parke-Davis, Esperion, and Pfizer. Most recently, he was the Senior Director, head of the Drug Safety Evaluation, and a member the Senior Leadership Team at Esperion Therapeutics, a Pfizer Inc. company. Prior to that, Dr. Lalwani was Vice President of Drug Safety Evaluation at Esperion and played key leadership roles in the development of all of Esperion’s HDL therapy product candidates including ETC-216 (Apo-A1 Milano).
John F. Paolini, M.D., P.h.D, F.A.C.C.
Chief Medical Officer
Dr. Paolini is a specialist in clinical development and research in cardiovascular disease. Most notably, he worked at Merck & Co., Inc developing novel therapies for dislipidemic patients (Tredaptive®, the Nicotinic acid/laropripant combination; Vytorin®/Inegy®, the Ezetimibe/Simvastatin combination tablet), and at Bayer Healthcare Pharmaceuticals, where he led the clinical development program for a novel anticoagulant agent for patients with atrial fibrillation (Xarelto,® the direct factor Xa inhibitor, rivaroxaban). He is board certified in Cardiovascular Disease, a Fellow of the American College of Cardiology and has served as a Clinical Associate in Cardiovascular Medicine at the Hospital of the University of Pennsylvania.
Constance Keyserling, M.S.
Sr. Vice President, Clinical Development
Ms. Keyserling has more than 20 years of global clinical development experience at Parke-Davis, Pfizer, Esperion, and QuatRx. She was previously Vice president of Development Operations at QuatRx. Prior to that, Ms. Keyserling was senior director of operations at Esperion, where her responsibilities included clinical program design and management, clinical outsourcing, regulatory operations and SOP systems development.
Cyrille Tupin, C.P.A.
Vice President, Finance
Mr. Tupin previously was Audit Director of Sygnatures, the largest private audit and consultant company in Toulouse, France. Prior to that, Mr. Tupin spent more than seven years with PricewaterhouseCoopers. He has worked on a number of high-profile business transactions including the Alcan Group takeover bid for Pechiney and the consolidation audit of Pechiney for Alcan. Mr. Tupin has been a French CPA since 2002.
Ronald Barbaras, Ph.D.
Senior Director, Biology
A biochemist, Dr. Barbaras has an extensive background in HDL research, including lipoprotein binding and cholesterol synthesis. Dr. Barbaras was formerly the Director of Research and group leader in ATP synthase, HDL metabolism and immunomodulation at Institut National de la Santé et de la Recherche Médicale (INSERM), the French public research institution dedicated to biological, medical and public health research.
Daniela Oniciu, Ph.D.
Senior Director, Chemistry
Prior to joining Cerenis, Dr. Oniciu previously was Director of Chemistry at Esperion. She was a co-inventor of small molecule drugs that were in development at Esperion and also served as co-chair of the preclinical research team. Following the acquisition of Esperion by Pfizer, Dr. Oniciu remained Associate Director of Chemistry until December 2004.
J. Christopher Prue, R.Ph., M.B.A.
Vice President, Regulatory Affairs
Mr. Prue has more than 30 years of experience in the pharmaceutical industry, with a broad knowledge of regulatory operations. He formerly held roles at AtheroGenics, Purdue Pharma, Incara Pharmaceuticals, Glaxo Wellcome, and The Upjohn Company. At Cerenis, Mr. Prue oversees the Company's regulatory, pharmacovigilance and quality assurance efforts.